dc.creator | Papadaki M.A., Messaritakis I., Fiste O., Souglakos J., Politaki E., Kotsakis A., Georgoulias V., Mavroudis D., Agelaki S. | en |
dc.date.accessioned | 2023-01-31T09:42:02Z | |
dc.date.available | 2023-01-31T09:42:02Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.3390/ijms22020925 | |
dc.identifier.issn | 16616596 | |
dc.identifier.uri | http://hdl.handle.net/11615/77536 | |
dc.description.abstract | We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre-and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs: p = 0.004), CEACAM5mRNA (p = 0.010), or by any assay (p = 0.000) was associated with disease progression. Reduced survival was demonstrated for patients harboring ≥5 CTCs (progression-free survival; PFS: p = 0.000; overall survival; OS: p = 0.009), CEACAM5mRNA+ CTCs (PFS: p = 0.043; OS: p = 0.039), and CTCs by any assay (PFS: p = 0.005; OS: p = 0.006, respectively). CTC-detection by any assay independently predicted for increased risk of relapse (hazard ratio; HR: 3.496; p = 0.001) and death (HR: 2.866; p = 0.008). CellSearch-positivity either pre-, post-1st, or post-2nd cycle, was predictive for shorter PFS (p = 0.036) compared to negativity in all time points. Persistent CEACAM5mRNA-positivity pre-and post-treatment was associated with reduced PFS (p = 0.036) and OS (p = 0.026). In conclusion, CTC detection and monitoring using the CellSearch and CEACAM5mRNA assays provides valuable and complementary clinical information for chemo-naïve advanced or metastatic NSCLC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | en |
dc.language.iso | en | en |
dc.source | International Journal of Molecular Sciences | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100098210&doi=10.3390%2fijms22020925&partnerID=40&md5=3f9903f7b86eab839d1f9f0dffbfc714 | |
dc.subject | anaplastic lymphoma kinase | en |
dc.subject | docetaxel | en |
dc.subject | epidermal growth factor receptor | en |
dc.subject | gemcitabine | en |
dc.subject | messenger RNA | en |
dc.subject | pemetrexed | en |
dc.subject | taxane derivative | en |
dc.subject | vinorelbine tartrate | en |
dc.subject | carcinoembryonic antigen | en |
dc.subject | CEACAM5 protein, human | en |
dc.subject | glycosylphosphatidylinositol anchored protein | en |
dc.subject | tumor marker | en |
dc.subject | adult | en |
dc.subject | advanced cancer | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | bone metastasis | en |
dc.subject | cancer chemotherapy | en |
dc.subject | cancer combination chemotherapy | en |
dc.subject | cancer patient | en |
dc.subject | cancer risk | en |
dc.subject | cancer staging | en |
dc.subject | cancer survival | en |
dc.subject | central nervous system metastasis | en |
dc.subject | circulating tumor cell | en |
dc.subject | clinical article | en |
dc.subject | controlled study | en |
dc.subject | disease exacerbation | en |
dc.subject | drug efficacy | en |
dc.subject | female | en |
dc.subject | HCC827 cell line | en |
dc.subject | human | en |
dc.subject | human cell | en |
dc.subject | human tissue | en |
dc.subject | liquid biopsy | en |
dc.subject | liver metastasis | en |
dc.subject | lung metastasis | en |
dc.subject | male | en |
dc.subject | metastasis | en |
dc.subject | monotherapy | en |
dc.subject | non small cell lung cancer | en |
dc.subject | overall survival | en |
dc.subject | peripheral blood mononuclear cell | en |
dc.subject | progression free survival | en |
dc.subject | real time polymerase chain reaction | en |
dc.subject | blood | en |
dc.subject | disease free survival | en |
dc.subject | metabolism | en |
dc.subject | metastasis | en |
dc.subject | middle aged | en |
dc.subject | non small cell lung cancer | en |
dc.subject | pathology | en |
dc.subject | prognosis | en |
dc.subject | tumor embolism | en |
dc.subject | tumor recurrence | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Biomarkers, Tumor | en |
dc.subject | Carcinoembryonic Antigen | en |
dc.subject | Carcinoma, Non-Small-Cell Lung | en |
dc.subject | Disease-Free Survival | en |
dc.subject | Female | en |
dc.subject | GPI-Linked Proteins | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Metastasis | en |
dc.subject | Neoplasm Recurrence, Local | en |
dc.subject | Neoplastic Cells, Circulating | en |
dc.subject | Prognosis | en |
dc.subject | MDPI AG | en |
dc.title | Assessment of the efficacy and clinical utility of different circulating tumor cell (CTC) detection assays in patients with chemotherapy-naïve advanced or metastatic non-small cell lung cancer (NSCLC) | en |
dc.type | journalArticle | en |